Phase I – Bioequivalence

302 trials 14 recruiting

Filter these 302 trials by condition, country, sponsor and more.

Open in Search →

Bioequivalence clinical trial of two formulations of hydrochlorothiazide. Ended

2023-505692-72-00 Healthy volunteers 2023-07-18
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors Ended

2022-501317-31-00 Solid tumor 2023-06-29
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended

2023-504523-83-00 No medical condition 2023-06-29
Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended

2023-504527-40-00 No medical condition 2023-06-29
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended

2023-504987-40-00 Healthy volunteers 2023-06-26
Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease Ended

2024-517758-87-00 Nontuberculous mycobacterial disease 2023-06-22
Randomized, open-label, single dose, two-period, cross-over bioequivalence study comparing test formulation Rosuvastatin/Amlodipine/Ramipril… Ended

2023-503822-38-00 Not applicable (submitted trial is a bioequivalence stu 2023-06-19
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product P… Ended

2023-504132-18-00 N.A. (submitted trial is a bioequivalence study in heal 2023-06-19
A Single Dose, Fast State, Bioequivalence Study of CEFIXIMA ATB 400 mg Hard Capsules (Antibiotice S.A.) vs. CEFIXORAL® 400 mg Film Coated Ta… Ended

2023-504011-33-00 healthy subjects 2023-06-12
Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy… Ended

2023-503557-35-00 thromboembolism 2023-06-08
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions Ended

2022-502701-15-00 Thrombocytopenia 2023-06-07
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2023-505237-27-00 Healthy volunteers 2023-06-02
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions. Ended

2022-502702-32-00 Aplastic anemia 2023-05-30
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tab… Ended

2022-502814-99-00 Non-small cell lung cancer (NSCLC) 2023-05-30
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product P… Ended

2023-503345-59-00 Not applicable (submitted trial is a bioequivalence stu 2023-05-23
A Randomized, Open-label, Single Dose, 3-Period, 6-Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Apraglutide Vers… Ended

2023-504430-22-00 Healthy 2023-05-23
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended

2022-501327-25-00 Advanced or recurrent endometrial carcinoma in adults w 2023-05-13
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Subjects Ended

2022-501514-56-00 Male hypogonadism 2023-05-02
A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in… Ended

2022-502385-24-00 Heart failure with left ventricular ejection fraction ≥ 2023-04-27
Bioequivalence clinical trial of two formulations of apixaban Ended

2023-503970-19-00 Healthy volunteers 2023-03-31
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2022-503083-32-00 Healthy volunteers 2023-03-08
A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intram… Ended

2022-502179-48-00 Schizophrenia 2023-02-23
Bioequivalence of Oxazepam 50 mg Orodispersible Tablets Versus Seresta® 50 mg Tablets in Healthy Subjects. Ended

2022-501135-16-00 No medical condition is being investigated. This is a c 2022-12-26
Bioequivalence clinical trial of two formulations of rosuvastatin/ezetimibe. Ended

2022-501862-24-00 Healthy volunteers 2022-11-25